ME-401

April 6, 2020April 6, 2020

ME-401 Put on FDA’s Fast Track for Previously Treated Follicular Lymphoma

News

The U.S. Food and Drug Administration (FDA) has granted fast track designation to MEI Pharma‘s investigational compound ME-401 for treating follicular lymphoma patients who received at least two prior therapies. A ... Read more

October 25, 2019

Durable Responses Seen to ME-401 in Advanced Follicular Lymphoma and CLL/SLL Patients in Ongoing Trial

News

MEI Pharma’s experimental compound ME-401 reduced tumor burden in 78% of patients with relapsed or refractory follicular lymphoma and in 89% of those with relapsed or refractory chronic lymphocytic leukemia or ... Read more

June 14, 2019

ME-401 Experimental Compound Reduces Tumor Burden in Follicular Lymphoma, Phase 1 Trial Shows

News

MEI Pharma‘s experimental compound ME-401 reduced tumor burden in 80% of patients with relapsed or refractory follicular lymphoma in a Phase 1 trial, the company said. Responses were comparable among ... Read more

October 18, 2018

MEI Pharma, BeiGene Will Evaluate New Combo Therapy for B-cell Cancers

News

A recent collaboration between MEI Pharma and BeiGene will test a combination of two investigational cancer therapies, ME-401 and zanubrutinib, for treating patients with B-cell cancers. Under the new partnership, MEI Pharma will amend its ongoing ... Read more

May 2, 2016May 2, 2016

New PI3K Delta Inhibitor to Treat Blood Cancers Shows Promise in Early Clinical Study

News

MEI Pharma recently presented promising clinical results from a new oral phosphatidylinositol 3 kinase (PI3K) delta inhibitor, ME-401, that may improve the therapeutic window in cancer patients compared to other PI3K ... Read more